Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA in the U.S. for adult patients with chronic lymphocytic
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period
Launched BRUKINSA® in the U.S. for adult patients with chronic. | May 4, 2023
Recorded product revenue of $349.5 million for the third quarter, representing an 82% increase from $192.5 million in the prior-year period BRUKINSA product revenue totaled $155.5 million, increasing
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17 novavax.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from novavax.com Daily Mail and Mail on Sunday newspapers.